

Supplemental Data

Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation.

Maria A. Garcia et. al.

Supplemental Tables

Supplemental Figures

Study Group Membership

Supplemental Table 1. Demographic features and CSF characteristics of healthy and disease controls						
Group	Age (median, IQR) years	Sex (male %)	Cerebrospinal Fluid			
			WCC >5 cells/ μ L (n)	Protein >45 mg/dL (n)	hsCRP >0.2 mg/L	D-dimer >0.19 mg/L
Healthy Controls N=14	67.5 (51–75)	57.1%	1/14	6/14	0/13	3/11
Autoimmune encephalitis N=14	37.5 (23–53)	42.8%	5/14	3/14	1/13	1/8
Acute meningitis N=12	50.5 (28–67.5)	50%	11/12	10/12	0/9	5/9
Acute encephalitis N=11	62 (32–65)	54.5%	6/11	7/11	0/7	3/6
Neuro- Sarcoidosis N=12	54 (47.5–65.5)	33.4%	7/12	9/12	0/10	7/9
Neuro Myelitis Optica N=11	33 (26–48)	19%	6/11	5/11	0/7	2/7
Stroke N=8	44 (39.5–50.5)	75%	3/8	5/8	0/8	4/7

Supplemental Table 2. Characteristics of the CSF as related with anti-SARS-CoV2 IgG and IgA antibodies								
ID #	COVID-19 Diagnostic Group	CSF WCC cell/ μ L	CSF RBC cell/ μ L	CSF Protein mg/dL	IgG index	Q Alb	CSF Anti-SARS-Cov2 IgG Units ^A	CSF Anti-SARS-Cov2 IgA Units ^B
1	Stroke/SAH	313	152000	56	NA	NA	3.68	10.26
2	Stroke/ Ischemic	0	15	5.5	NA	NA	0.76	0.42
3	Stroke/SAH	5	2000	85	NA	NA	NA	NA
5	Stroke/ Ischemic/C- HIS	18	6000	277	NA	NA	12.29	0.76
7	Stroke/ Ischemic/C-HIS	1	0	26	0.55 ^C	3.65	29.54	10.26
9	Stroke/ Ischemic and ICH	56	2000	63	NA	NA	5.11	0.47
4	Encephalopathy/ C-HIS	1	9	54	NA	NA	6.80	1.38
6	Encephalopathy/ C-HIS	25	1000	31	NA	NA	7.75	5.76
12	Encephalopathy/ C-HIS	0	0	52	NA	NA	1.36	0.62
13	Encephalopathy/ C-HIS	1	99	56	0.62 ^C	7.95	0.66	0.90
15	Encephalopathy	1	0	31	0.43 ^C	3.84	0.03	0.30
16	Encephalopathy	1	160	62	0.72 ^C	8.88	4.12	1.59
17	Encephalopathy	3	0	30	0.38	4.53	16.12	3.17
8	Headache/other	1	109	23	NA	NA	3.76	0.50
10	Headache/ other	3	0	33	NA	NA	1.60	0.13
11	Headache/ other	0	1	35	NA	NA	2.93	5.04
14	Headache/ other	3	0	27	0.52 ^C	5.06	6.92	1.46
18	Headache/ other	1	27	27	0.50	4.02	0.06	0.03

^A Cutoff for IgG positivity at 1.23 units. Positive values are in bold.

^B Cutoff for IgG positivity at 5.0 units. Positive values are in bold.

^C Oligoclonal bands tested negative in CSF and serum


Abbreviations: SAH: subarachnoid hemorrhage; Q Alb: albumin quotient; ICH: intra-cerebral hemorrhage; C-HIS: COVID-19 hyper inflammatory syndrome

Supplemental Table 3.

Percentage of detection of CSF biomarkers in CSF from COVID-19 and controls

Analyte/Group % analyte detection	Healthy controls (n=12)	COVID- 19 (n=18)	Acute meningitis (n=12)	Autoimmune Encephalitis (n=11)	Acute Encephalitis (n=11)	NMO (n=11)	Neuro- Sarcoidosis (n=11)	Stroke (n=8)
IL-6 (LLQ=0.017 pg/mL)	12 100.0%	18 100.0%	12 100.0%	10 90.9%	10 90.9%	10 90.9%	11 100.0%	6 75.0%
IL-10 (LLQ=0.03 pg/mL)	10 83.3%	15 83.3%	10 83.3%	9 81.8%	6 54.5%	6 54.5%	11 100.0%	4 50.0%
TNFα (LLQ= 0.018 pg/mL)	11 91.7%	17 94.4%	12 100.0%	10 90.9%	9 81.8%	9 81.8%	11 100.0%	6 75.0%
IFNγ (LLQ=0.082 pg/mL)	11 91.7%	16 88.9%	11 91.7%	10 90.9%	10 90.9%	11 100.0%	11 100.0%	7 87.5%
IL12p70 (LLQ=0.02 pg/mL)	7 58.3%	13 72.2%	11 91.7%	8 72.7%	6 54.5%	7 63.6%	10 90.9%	5 62.5%
IL-17A (LLQ=0.003 pg /mL)	11 91.7%	18 100.0%	12 100.0%	9 81.8%	9 81.8%	10 90.9%	11 100.0%	8 100.0%
NF-light (LLQ= 1.6 pg/mL)	12 100.0%	18 100.0%	12 100.0%	10 90.9%	11 100.0%	11 100.0%	11 100.0%	8 100.0%
Ferritin ng/mL	11 91.7%	17 94.4%	9 75%	10 90.9%	7 63.6%	7 63.6%	9 81.8%	7 87.5%
D-dimer (LLQ= 0.19 mg/L	10 83.3%	15 83.3%	9 75%	6 54.5%	6 54.5%	7 63.6%	8 72.7%	8 100.0%
hs-CRP (LLQ=0.2 mg/L	11 91.7%	17 94.4%	9 75%	10 90.9%	7 63.6%	7 63.6%	9 81.8%	8 100.0%

Abbreviations: LLQ: lower limit of quantification



Supplementary Figure 1.

Scatter plot below distribution of the SARS-CoV2 IgG and IgA antibody measurements in the 37 CSF samples testes, 17 COVID-19 cases and 30 controls. Thirteen of 37 cases tested were positive, all of them COVID-19 cases. IgA was positive only in 4 of the 37 cases, and all of these 4 were also COVID-19 cases positive for IgG. The dotted line represents the cutoff for positivity: 1.23 units for IgG and 5 units for IgA. The scale is logarithmic.

Supplemental Table 4.
Johns Hopkins Neuro-COVID-19 Group

Name		Location	Contribution
Andrew Agostini	M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Mona Bahout	M.D, Ph.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Srishti Bhagat	M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Pavan Bhargava	M.B.B.S., M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Sung-Min Cho	D.O., M.H.S.	Department of Neurology, Division of Cardiac Surgery, Cardiac Surgical Intensive Care, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Camilo Diaz Cruz	M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Sachin Gadani	M.D, Ph.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data,
Rebecca Gottesman	M.D. Ph.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Provided advice about study design, statistical analysis and revised the manuscript for intellectual content
Brittney M.Howard	M.S.	Department of Pathology,	Laboratory testing, acquired laboratory data and revised the

		Johns Hopkins University School of Medicine	manuscript for intellectual content
George Kannarkat	M.D., Ph.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Amir Kheradmand	M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Michael Kornberg	M.D., M.S., Ph.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Rafael Llinas	M.D	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Justin McArthur	M.B.B.S., M.P.H	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Bipasha Mukherjee	M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
John C. Probasco	M.D	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Alexandra Simpson	M.D	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Jose Ignacio Suarez	M.D	Departments of Neurology and Neurosurgery, Anesthesiology and Critical Care Medicine, Johns Hopkins	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content

		University School of Medicine.	
Victor C. Urrutia	M.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Arun Venkatesan	M.D. Ph.D.	Department of Neurology, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content
Wendy Ziai	M.D	Departments of Neurology and Neurosurgery, Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine.	Evaluation of patients, acquired clinical data, and revised the manuscript for intellectual content